http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107073039-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2015-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107073039-B |
| titleOfInvention | Immunotherapy for cancer treatment |
| abstract | Methods of treating cancer using Double Negative (DN) T cells are described. DNTs are useful for the treatment of chemotherapy-resistant cancers such as recurrent or relapsed Acute Myeloid Leukemia (AML). Also described is the use of allogeneic DNTs (such as those derived from healthy donors) that do not exhibit toxicity to normal host tissues and complications associated with graft-versus-host disease. |
| priorityDate | 2014-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.